Zhejiang Tianyu Pharmaceutical Co Ltd

300702.CS▼

Tianyu Pharma's 2026 interim net profit was 104 million yuan, down 32.12% year on year

Tianyu Pharma released its 2026 interim report. Total operating revenue was 2.011 billion yuan, and net profit attributable to the parent company was 104 million yuan, down 32.12% from the same period last year. Net cash inflow from operating activities was 416 million yuan, the asset-liability ratio was 47.65%, the gross margin was 30.14%, and diluted earnings per share was 0.30 yuan. The company had 14,100 shareholders, and the top ten shareholders held 66.08% of the shares.

300702.CS ▼

Jiemian·22dRead more →

300702.CS▲

Tianyu Pharmaceutical's Wholly-Owned Subsidiary Obtains Drug Registration Certificate for Vardenafil Hydrochloride Tablets

Zhejiang Nuode Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Zhejiang Tianyu Pharmaceutical Co., Ltd., recently received the Drug Registration Certificate for Vardenafil Hydrochloride Tablets issued by the National Medical Products Administration. The specification is 10 mg, indicated for the treatment of male erectile dysfunction. The drug registration classification is chemical drug category 4, and the approval number is valid until August 3, 2031. According to data from Menet, the drug's sales in domestic sample hospitals and urban brick-and-mortar pharmacies in 2025 were approximately 14 million yuan. As of July 31, 2026, the company's cumulative R&D investment in this product was approximately 6.63 million yuan. The company stated that this approval will further enrich its formulation portfolio and is expected to increase formulation business revenue, but drug sales are affected by factors such as changes in the market environment, and profitability is uncertain.

300702.CS ▲

Jiemian·44dRead more →

300702.CS▲

Tianyu Pharmaceutical's Two Drugs Tentatively Selected for the 12th National Drug Procurement

Zhejiang Tianyu Pharmaceutical's wholly owned subsidiary Zhejiang Nuode Pharmaceutical has had its trazodone hydrochloride tablets and edoxaban tosylate tablets tentatively selected for the 12th round of national centralized drug procurement. The trazodone hydrochloride tablets are in a 50 mg strength, while the edoxaban tosylate tablets come in 15 mg, 30 mg, and 60 mg strengths. The procurement period runs from the effective date of the selection results until December 31, 2029. Trazodone hydrochloride tablets are used to treat depression, with domestic sales of approximately 100,600 yuan in the first quarter of 2026. Edoxaban tosylate tablets are used for stroke prevention in non-valvular atrial fibrillation and for treating deep vein thrombosis, with sales of about 67,500 yuan in 2025 and roughly 103,800 yuan in the first quarter of 2026. The company stated that if the subsequent procurement contracts are successfully signed and implemented, it will help boost sales volume and market share, but there remains uncertainty regarding the signing of procurement agreements and the impact on company performance.

300702.CS ▲

Jiemian·46dRead more →

300702.CS

Tianyu Pharma's Brexpiprazole API Passes CDE Review

Zhejiang Tianyu Pharmaceutical announced that its brexpiprazole active pharmaceutical ingredient has recently passed the review of the Center for Drug Evaluation of the National Medical Products Administration and obtained registration approval. The API registration number is Y20240001143, and it is indicated for the treatment of schizophrenia in adults. Currently, a total of 21 manufacturers in China have passed the CDE technical review, including Tianyu Pharma. The company stated that the API still needs to obtain a GMP compliance inspection result of "compliant" from the Zhejiang Medical Products Administration before it can be marketed and sold in China. The application is currently being prepared, and the timing of market launch remains uncertain.

300702.CS

Jiemian·68dRead more →